Tactical Therapeutics Overview

  • Founded
  • 2005
Founded
  • Status
  • Private
  • Employees
  • 1
Employees
  • Latest Deal Type
  • Series B
  • (Upcoming)
  • Latest Deal Amount
  • $50M
Latest Deal Amount

Tactical Therapeutics General Information

Description

Developer of a therapeutic drug intended to help with the treatment of glioblastoma (GBM). The company's drug includes a novel, orally-administered small molecule that is a First-in-Class non-voltage Calcium Signal inhibitor and inhibits angiogenesis, metastasis, and tumor cell proliferation by addressing multiple pathways, thereby inhibiting several solid cancers and GBM, the drug (Carboxyamidotriazole Orotate, CTO) crosses the blood-brain-barrier, shows a safe toxicity profile and circumvents resistance in brain cancer, CTO inhibits replication of SARS-CoV-2 and most cytokines recorded in COVID-19 "cytokine storm.", enabling physicians to overcome resistance in malignant brain cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 48 Wall Street
  • 12th Floor
  • New York, NY 10005
  • United States
+1 (917) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tactical Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series B) $50M Upcoming Clinical Trials - Phase 2
1. Early Stage VC (Series A) Completed Startup
To view Tactical Therapeutics’s complete valuation and funding history, request access »

Tactical Therapeutics Patents

Tactical Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3027776-A4 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Pending 02-Aug-2013 0000000000 0
AU-2014296212-B2 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Active 02-Aug-2013 0000000000 0
JP-6913459-B2 Methods and molecular pharmacodynamic biomarkers for a wide variety of signaling pathways in orotic acid carboxamide triazole responses Active 02-Aug-2013 0000000000
US-10378059-B2 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Active 02-Aug-2013 0000000000 0
US-20150038349-A1 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Granted 02-Aug-2013 C12Q1/6809

Tactical Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Rashida Karmali Ph.D Founder, Chief Executive Officer, President & Chairman
To view Tactical Therapeutics’s complete executive team members history, request access »

Tactical Therapeutics Board Members (2)

Name Representing Role Since
Rashida Karmali Ph.D Tactical Therapeutics Founder, Chief Executive Officer, President & Chairman 000 0000
You’re viewing 1 of 2 board members. Get the full list »

Tactical Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial